CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

Group 1 - CG Oncology, Inc. (NASDAQ: CGON) reported positive results from its phase 3 BOND-003 study for the oncolytic immunotherapy candidate Cretostimogene, targeting BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) [2] - The study's results indicate a significant advancement in treatment options for patients with NMIBC who do not respond to BCG therapy [2] - The Biotech Analysis Central service offers extensive resources for investors, including a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2]